Iron and atherosclerosis

Authors: P. Riško
Authors‘ workplace: II. interní klinika 3. LF UK a FN Královské Vinohrady, Praha
Published in: Kardiol Rev Int Med 2016, 18(4): 272-275


Atherosclerosis remains the leading cause of death. It is a complex fibroproductive "reparative" inflammatory process, which takes place in the arterial wall. The set of these processes is mainly caused by monocytes/macrophages, B and T lymphocytes, endothelial cells and smooth muscle cells. The article describes the role of iron in individual steps of the pathogenesis of atherosclerosis, the second part summarises various clinical studies investigating the association between iron and the occurrence of cardiovascular diseases.

atherosclerosis – iron – cardiovascular disease


1. Kannel WB, Hjortland MC, McNamara PM et al. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976; 85(4): 447– 452. doi:10.7326/ 0003-4819-85-4-447.

2. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; 1(8233): 1293– 1294. doi: 10.1016/ S0140-6736(81)92463-6.

3. Schächinger V, Zeiher AM. Atherogenesis –  recent insights into basic mechanisms and their clinical impact. Nephrol Dial Transplant 2002; 17(12): 2055– 2064. doi: 10.1093/ ndt/ 17.12.2055.

4. Chau LY. Iron and atherosclerosis. Proc Natl Sci Counc Repub China B 2000; 24(4): 151– 155.

5. Yoshimura T, Leonard EJ. Human monocyte chemoattractant protein-1 (MCP-1). Adv Exp Med Biol 1911; 305: 47– 56. doi: 10.1007/ 978-1-4684-6009-4_6.

6. Jessup W, Kritharides L. Metabolism of oxidized LDL by macrophages. Curr Opin Lipidol 2000; 11(5): 473– 481.

7. Schrijvers DM, De Meyer GRY, Herman AG et al. Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability. Cardiovasc Res 2007; 73(3): 470– 480. doi: 10.1016/ j.cardiores.2006.09.005.

8. Vallelian F, Pimenova T, Pereira CP et al. The reaction of hydrogen peroxide with hemoglobin induces extensive alpha-globin crosslinking and impairs the interaction of hemoglobin with endogenous scavenger pathways. Free Radic Biol Med 2008; 45(8): 1150– 1158. doi: 10.1016/ j.freeradbio­med.2008.07.013.

9. Yuan XM, Li W, Baird SK et al. Secretion of ferritin by iron-laden macrophages and influence of lipoproteins. Free Radic Res 2004; 38(10): 1133– 1142. doi: 10.1080/ 10715760400011692.

10. DePalma RG, Hayes VW, Cafferata HT et al. Cytokine signatures in atherosclerotic claudicants. J Surg Res 2003; 111(2): 215– 221. doi: 10.1016/ S0022-4804(03)00075-1.

11. Yuan XM, Li W. Iron involvement in multiple signaling pathways of atherosclerosis: a revisited hypothesis. Curr Med Chem 2008; 15(21): 2157– 2172. doi: 10.2174/ 092986708785747634.

12. Brånén L, Hovgaard L, Nitulescu M et al. Inhibition of tumornecrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004; 24(11): 2137– 2142. doi: 10.1161/ 01.ATV.0000143933.20616.1b.

13. Seligman PA, Kovar J, Schleicher RB et al. Transferrin-independent iron uptake supports B lymphocyte growth. Blood 1991; 78(6): 1526– 1531.

14. Weiss G, Wachter H, Fuchs D. Linkage of cell mediated immunity to iron metabolism. Immunol Today 1995; 16(10): 495– 500. doi: 10.1016/ 0167-5699(95)80034-4.

15. Yuan XM, Li W. Iron involvement in multiple signaling pathways of atherosclerosis: a revisited hypothesis. Curr Med Chem 2008; 15(21): 2157– 2172. doi: 10.2174/ 092986708785747634.

16. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 1990; 75(9): 1870– 1876.

17. Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J 1989; 117(5): 1177– 1188.

18. Salonen JT, Nyyssonen K, Korpela H et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86(3): 803– 811. doi: 10.1161/ 01.CIR.86.3.803.

19. Tuomainen TP, Punnonen K, Nyyssonen K et al. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998; 97(15): 1461– 1466. doi: 10.1161/ 01.CIR.97.15.1461.

20. van der A DL, Grobbee DE, Roest M et al. Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke 2005; 36(8): 1637– 1641. doi: 10.1161/ 01.STR.0000173172.82880.72.

21. Kiechl S, Willeit J, Egger G et al. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997; 96(10): 3300– 3307. doi: 10.1161/ 01.CIR.96.10.3300.

22. Wolff B, Volzke H, Ludemann J et al. Association between high serum ferritin levels and carotid atherosclerosis in the study of health in Pomerania (SHIP). Stroke 2004; 35(2): 453– 457. doi: 10.1161/ 01.STR.0000114875.31599.1C.

23. Roughead ZK, Hunt JR. Adaptation in iron absorption: iron supplementation reduces nonheme-iron but not heme-iron absorption from food. Am J Clin Nutr 2000; 72(4): 982– 989.

24. Zhang W, Iso H, Ohira T et al. Associations of dietary iron intake with mortality from cardiovascular disease: the JACC study. J Epidemiol 2012; 22(6): 484– 493. doi: 10.2188/ jea.JE20120006.

25. Kaluza J, Wolk A, Larsson SC. Heme iron intake and risk of stroke: a prospective study of men. Stroke 2013; 44(2): 334– 339. doi: 10.1161/ STROKEAHA. 112.679662.

26. Tuomainen TP, Kontula K, Nyyssonen K et al. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in eastern Finland. Circulation 1999; 100(12): 1274– 1279. doi: 10.1161/ 01.CIR.100.12.1274.

27. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood) 2007; 232(8): 1014– 1020. doi:10.3181/ 0703-MR-54.

28. Valenti L, Swinkels DW, Burdick L et al. Serum fer­ritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2011; 21(8): 568– 575. doi: 10.1016/ j.numecd.2010.01.003.

29. Rajapurkar MM, Shah SV, Lele SS et al. Association of catalytic iron with cardiovascular disease. Am J Cardiol 2012; 109(3): 438– 442. doi: 10.1016/ j.amjcard.2011.09.032.

30. Steen DL, Cannon CP, Lele SS et al. Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clin Cardiol 2013; 36(3): 139– 145. doi: 10.1002/ clc.22089.

31. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion 2002; 42(9): 1135– 1139. doi: 10.1046/ j.1537-2995.2002.00186.x.

32. Salonen JT, Tuomainen TP, Salonen R et al. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Dis­ease Risk Factor Study. Am J Epidemiol 1998; 148(5): 445– 451. doi: 10.1093/ oxfordjournals.aje.a009669.

33. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J 2011; 162(5): 949– 957.e1. doi: 10.1016/ j.ahj.2011.08.013.

34. Aronow WS. Serum ferritin is not a risk factor for coronay artery disease in men and women aged > 62 years. Am J Cardiol 1993: 72(3): 347– 348. doi: 10.1016/ 0002-9149(93)90684-5.

35. Moore M, Folsom AR, Barnes RW et al. No association between serum ferritin and asymp­tomatic carotid atherosclerosis. Am J Epidemiol 1995; 141(8): 719– 723.

36. Knuiman MW, Divitini ML, Olynyk JK et al. Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. Am J Epidemiol 2003; 158(2): 144– 149. doi: 10.1093/ aje/ kwg121.

37. Friedrich N, Milman N, Volzke H et al. Is serum fer­ritin within the reference range a risk predictor of cardiovascular disease? A population-based, long-term study comprising 2874 subjects. Br J Nutr 2009; 102(4): 594– 600. doi: 10.1017/ S000711450922085X.

Paediatric cardiology Cardiac surgery Cardiology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account